The concentrated sell-down by Cue Biopharma’s CEO after option exercises is a bearish signal for a pre-commercial biotech with binary catalyst risk. There is no insider buying to offset. Monitor for upcoming pipeline data readouts or capital needs announcements — if the selling continues, it may signal management skepticism about near-term catalysts.
Price Chart
Executive Summary
CEO Shao-Lee Lin sold ~$1.6M of CUE shares in open-market sales last week, and VP Meluzio sold ~$169K, both after exercising zero-cost stock options. At a ~$233M market cap, the CEO's total open-market sales represent ~0.7% of market cap — material enough to require scrutiny on sentiment, though multiple smaller transactions across days suggest planned selling. The cluster is entirely sells with no insider buying, generating a bearish tilt, especially given any upcoming catalyst-dependent re-rating without positive data.
Key Financial Metrics
Key Facts
- CEO Shao-Lee Lin sold ~$1.6M open-market across multiple days (Aug 12-13) at ~$27-30/share
- VP Meluzio sold ~$169K open-market on Aug 13 after exercising options
- Total open-market sells = ~$1.77M, representing ~0.76% of the $233M market cap
- All cash-out trades occurred after exercising zero-cost derivative grants — no insider buying in this window
- Prior 30 days show $1.6M in total insider sells, making this a continued selling pattern by the CEO
Financial Impact
CEO sold ~0.7% of market cap in open-market sales in a 2-day window; no buying to offset
Risk Factors
- CEO selling may spook retail and momentum investors ahead of binary Phase 2 data
- If near-term clinical catalysts fail, downside could accelerate without insider support
- High short interest possible given profile; no cash offsets to selling signal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CUE-1787005246867 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.45 (+1.18%) |
Oct 13, 2026 14d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.45 (−0.81%) |
Oct 8, 2026 19d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.45 (−17.38%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.45 (−34.74%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.45 (+23.06%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.45 (+28.21%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.45 (−33.25%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.45 (−46.05%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.45 (−49.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers